Research on depression portrays it as a complex brain-based condition shaped by biology, psychology and environment. A large body of work links depression to imbalances in neurotransmitters such as serotonin, dopamine, noradrenaline and GABA, as well as changes in brain circuits that regulate mood, motivation and stress responses. Imaging and postmortem studies reveal reduced volume or altered activity in regions like the prefrontal cortex, hippocampus and amygdala, often accompanied by dysregulated stress hormones such as cortisol.

Genetic studies show that vulnerability to depression is partly heritable, but no single gene is responsible. Instead, many small genetic effects interact with life events, trauma, chronic stress and social conditions. Inflammation and immune signaling also appear to contribute in some patients, suggesting that depression can be a systemic as well as a brain disorder.

Clinical research has evaluated multiple treatments. Antidepressant medications that act on serotonin and noradrenaline are widely used, but benefit varies and often appears modest in mild cases while clearer in more severe depression. Psychotherapies such as cognitive behavioral therapy and interpersonal therapy are strongly supported, with effects that can persist after treatment ends. Combining medication with psychotherapy often improves outcomes.

Newer approaches include rapid acting drugs that target glutamate signaling, neuromodulation techniques such as transcranial magnetic stimulation and deep brain stimulation, and lifestyle based interventions. Regular physical activity, better sleep, social support and structured daily routines all show protective and therapeutic value. Overall, research views depression as a heterogeneous condition requiring personalized, multi dimensional treatment and early intervention.